Katz, Amos

Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial

Olivotto, I., Oreziak, A., Barriales-Villa, R., Abraham, T. P., Masri, A., Garcia-Pavia, P., Saberi, S., Lakdawala, N. K., Wheeler, M. T., Owens, A., et al. (2020) · The Lancet

Cardiomyopathy and Myosin StudiesBlood Pressure and Hypertension Studies

Cited by 1,296

Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial

Anand, S. S., Bosch, J., Eikelboom, J. W., Connolly, S. J., Diaz, R., Widimsky, P., Aboyans, V., Alings, M., Kakkar, A. K., Keltai, K., et al. (2018) · The Lancet

Antiplatelet Therapy and Cardiovascular DiseasesPeripheral Artery Disease Management

Cited by 879

Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial

Connolly, S. J., Eikelboom, J. W., Bosch, J., Dagenais, G., Dyal, L., Lanas, F., Metsarinne, K., O'Donnell, M., Dans, A. L., Ha, J.-W., et al. (2018) · The Lancet

Antiplatelet Therapy and Cardiovascular DiseasesAcute Myocardial Infarction Research

Cited by 754

J-Point Elevation in Survivors of Primary Ventricular Fibrillation and Matched Control Subjects

Rosso, R., Kogan, E., Belhassen, B., Rozovski, U., Scheinman, M. M., Zeltser, D., Halkin, A., Steinvil, A., Heller, K., Glikson, M., et al. (2008) · Journal of the American College of Cardiology

Cardiac electrophysiology and arrhythmiasCardiovascular Effects of Exercise

Cited by 566

Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial

Ray, K. K., Colhoun, H. M., Szarek, M., Baccara-Dinet, M., Bhatt, D. L., Bittner, V. A., Budaj, A. J., Diaz, R., Goodman, S. G., Hanotin, C., et al. (2019) · The Lancet Diabetes & Endocrinology

Lipoproteins and Cardiovascular HealthDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 315

Evaluation of Ranolazine in Patients With Type 2 Diabetes Mellitus and Chronic Stable Angina

Kosiborod, M., Arnold, S. V., Spertus, J. A., McGuire, D. K., Li, Y., Yue, P., Ben-Yehuda, O., Katz, A., Jones, P. G., Olmsted, A., et al. (2013) · Journal of the American College of Cardiology

Heart rate and cardiovascular healthDiabetes Treatment and Management

Cited by 205

Lipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL Cholesterol

Schwartz, G. G., Szarek, M., Bittner, V. A., Diaz, R., Goodman, S. G., Jukema, J. W., Landmesser, U., López-Jaramillo, P., Manvelian, G., Pordy, R., et al. (2021) · Journal of the American College of Cardiology

Lipoproteins and Cardiovascular HealthAcute Myocardial Infarction Research

Cited by 150

Apolipoprotein B, Residual Cardiovascular Risk After Acute Coronary Syndrome, and Effects of Alirocumab

Hagström, E., Steg, P. G., Szarek, M., Bhatt, D. L., Bittner, V. A., Danchin, N., Diaz, R., Goodman, S. G., Harrington, R. A., Jukema, J. W., et al. (2022) · Circulation

Lipoproteins and Cardiovascular HealthAcute Myocardial Infarction Research

Cited by 118

Oral PCSK9 Inhibitor Enlicitide Versus Oral Nonstatin Therapies

Catapano, A. L., Mikhailova, E., Navar, A. M., Banka, P., Corral, P., Saxena, M., Steg, P. G., Verma, S., Kordahi, A. Y., Mendizabal, G., et al. (2026) · JACC

Lipoproteins and Cardiovascular HealthCholesterol and Lipid Metabolism

Cited by 19